Ascendiant Capital Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7.5
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Lucid Diagnostics (NASDAQ:LUCD) but lowers the price target from $8 to $7.5.
June 06, 2024 | 5:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Lucid Diagnostics but lowers the price target from $8 to $7.5.
The maintained Buy rating suggests continued confidence in Lucid Diagnostics' prospects, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100